PharmaFocus Today – Page 86 – media

Baide Medical’s stock surged 624%

On December 31, 2024 Eastern Time, Baird Medical Investment Holdings Ltd surged 623.81%. Baird Medical Investment Holdings Limited (hereinafter referred to as “Baird Medical”) is the substantive holding company of Baird (Suzhou) Medical Co., Ltd. Baide Medical officially went public on NASDAQ in the United States on October 2, 2024, through the backdoor acquisition of SPAC (Special Purpose Acquisition Company) ExcelFin Acquisition (XFIN). Baide Medical is a leading microwave ablation medical enterprise in China. According to the data, based on the sales revenue and sales of microwave ablation needles in 2022, Baide Medical ranks first among the suppliers of microwave ablation medical equipment for treating thyroid nodules and breast lumps in China. In addition, based on sales revenue in 2022, the company is the third largest supplier of microwave ablation medical devices in China. 01. After being listed for 3 months, the stock is like riding a roller coaster On ...
- Source: drugdu
- 173
- January 7, 2025
Developing Protein based Artificial Neural Networks

Cells naturally process various classification cues, such as stress and developmental signals, to initiate cellular functions and produce different outcomes; Immune cells respond to threats based on detected signals; The p53 signaling pathway determines whether to repair damage or initiate self destruction to prevent cancer. Scientists have been working hard to create artificial systems that can replicate this decision-making process within cells. Most existing attempts rely on DNA or RNA, which require further translation into proteins to perform their functions, resulting in a slow and less direct process. Recently, researchers from Westlake University and California Institute of Technology have not used DNA or RNA based systems, but have designed a fully protein based system in living cells, consisting of de novo designed protein heterodimers and engineered viral proteases to construct decision circuits that can process multiple signals and make decisions based on these signals. The research team named the system ...
- Source: drugdu
- 174
- January 7, 2025
Novartis accused of commercial bribery

New York (Reuters) – The U.S. Federal Court of Appeals for the Second Circuit has reinstated a lawsuit against Novartis. The lawsuit was filed by Steven Camburn, a former Novartis sales representative, alleging that Novartis illegally paid kickbacks to doctors to induce them to promote its multiple sclerosis drug Gilenya. Camburn said Novartis paid doctors thousands of dollars and set up business banquets in high-end restaurants to let them speak at events that were nominally academic conferences but were actually social activities to promote Gilenya. ▍Reported many times In 2013, the whistleblower sued Novartis under the U.S. False Claims Act, claiming that it paid $3,500 to doctor speakers at academic events to promote the sales of Gilenya. However, the lawsuit was dismissed, and the whistleblower filed lawsuits in other courts many times afterwards. But they all failed due to lack of sufficient specific evidence. But this time, the pharmacist’s complaint ...
- Source: drugdu
- 217
- January 7, 2025
The first domestic product was approved, and stem cell drugs ushered in a historic beginning

On the evening of January 2, the State Food and Drug Administration conditionally approved the listing of Amymetocel injection applied by Bosheng Excellence Biotechnology (Beijing) Co., Ltd. (hereinafter referred to as “Bosheng Excellence”) through the priority review and approval procedure. This is China’s first stem cell therapy drug, used to treat acute graft-versus-host disease with failure of hormone therapy, mainly involving the digestive tract in patients over 14 years old. Graft-versus-host disease is one of the main complications after allogeneic hematopoietic stem cell transplantation, and may cause death in severe cases. Specifically, graft-versus-host disease is a type of multi-organ syndrome that occurs after allogeneic hematopoietic stem cell transplantation when lymphocytes from the donor attack the recipient’s tissues, manifested as tissue inflammation and fibrosis mainly involving the skin, gastrointestinal tract, liver, lungs and mucosal surfaces. Amymetocel injection is a human umbilical cord mesenchymal stem cell injection. Its listing provides a new ...
- Source: drugdu
- 172
- January 7, 2025
The winning bid price of five injections is “less than 1 yuan”, and the price reduction of Chinese medicine centralized procurement exceeds expectations

The results of the third batch of centralized procurement of Chinese patent medicines by the Procurement Alliance for Procurement of Produced Medicines were announced recently, and the price reduction of centralized procurement exceeded market expectations. This round of centralized procurement of Chinese patent medicines involves 20 product groups, and the purchased varieties are mainly Chinese patent medicines that are commonly used in clinical practice, with high purchase amounts and large usage, including oral Chinese patent medicines and Chinese medicine injections. According to the results of the proposed selection announced by the Hubei Medical Security Bureau, a total of 175 products are proposed to be selected, of which 165 are directly proposed to be selected and 10 are supplementary proposed to be selected. The Hubei Medical Security Bureau did not directly announce the average price reduction of the selected varieties, but according to the statistics of different brokerages, the average price ...
- Source: drugdu
- 221
- January 7, 2025
A hospital in Shanxi was accused of having medical staff suspected of participating in the sale of babies, and Datong set up an investigation team

On January 2, it was learned that in response to the online reports that relevant personnel of the First People’s Hospital of Datong City, Shanxi Province were suspected of participating in the sale of babies, Datong City set up a joint investigation team to conduct an investigation. Any violations of laws and disciplines found will be dealt with seriously in accordance with the law and discipline. According to @Fazhi Daily, it is reported that the doctor involved is Wang Mouqing, chief physician of the obstetrics department of the First Hospital of Datong City, Shanxi Province. In 2022, Wang Mouqing received a 15-year-old girl who was about to give birth, but the girl’s family did not want the child. At the same time, another couple who had failed to conceive after two IVF treatments also visited Wang Mouqing. Faced with this situation, Wang Mouqing introduced the two parties. In May of ...
- Source: drugdu
- 208
- January 7, 2025
Seilong Pharmaceutical’s subsidiary, Famotidine, receives approval for launching

Financial Update, January 1 – Seilong Pharmaceutical (002898) announced that its wholly-owned subsidiary, Hunan Seilong Pharmaceutical Co., Ltd., has recently received the approval notification for the listing application of Famotidine from the National Medical Products Administration. The valid period for this drug is 18 months, and the notification is effective until December 30, 2029, with a registration standard number of YBY77052024. Famotidine is primarily used to treat upper gastrointestinal bleeding caused by peptic ulcers, further enriching the company’s raw material pharmaceutical product pipeline. The company stated that specific production and sales conditions will be influenced by various internal and external environmental changes, which may lead to certain uncertainties. In the first three quarters of 2024, Seilong Pharmaceutical achieved revenue of 219 million yuan, with a net profit attributable to the parent company of -3.69 million yuan. https://finance.eastmoney.com/a/202501013284575136.html
- Source: drugdu
- 133
- January 6, 2025
The first generic version of the new dosage form of the “hematopoietic miracle drug” is released

On December 17, the Class 3 generic drug Eltrombopag ethanolamine dry suspension submitted by Zezheng Pharmaceutical was approved for marketing and deemed to have passed the review, becoming the first generic drug in China . Immune thrombocytopenia (ITP) is a common acquired bleeding disease. Platelets sensitized by platelet-specific autoantibodies are excessively destroyed by the mononuclear macrophage system, autoantibodies inhibit megakaryocytes from producing platelets and cytotoxicity, T cells directly lyse platelets, and antigen-specific T cell immune intolerance cause thrombocytopenia (<100×10^9/L). In clinical practice, glucocorticoids are the first-line drugs commonly used to treat ITP. However, since ITP is a chronic disease that requires long-term medication, the long-term use of glucocorticoids may produce a variety of adverse reactions. Eltrombopag is the world’s first small molecule non-peptide TPO receptor agonist approved for marketing. The drug can interact with the transmembrane domain of the human TPO receptor, initiate a signal cascade reaction, stimulate the proliferation ...
- Source: drugdu
- 139
- January 6, 2025
Yiming Biopharma Completes RMB 200 Million Pre-D Round Financing

Recently, Jiangsu Yiming Biotechnology Co., Ltd. (hereinafter referred to as “Yiming Biotechnology”) announced that it has successfully completed a new round of strategic financing of nearly 200 million yuan. This Pre-D round of financing was funded by Beijing Changping Industrial Development Investment Fund and Beijing Pharmaceutical and Health Industry The joint investment by the investment fund is another round of financing obtained by Yiming Bio after the C+ round of financing in April 2023. Yiming Bio said that as a bridge for ATMPs to go global and commercialize, it has received support from multiple investors in the current complex market environment. This round of financing will be used to further support the construction of Yiming Biopharma’s ATMPs CDMO commercial production base, promote technology iteration, enhance the service capabilities of the CDMO global service network, and consolidate the company’s core competitiveness in the ATMPs drug technology track. , creating a large ...
- Source: drugdu
- 182
- January 6, 2025
$135 million! Liraglutide is coming from China

Recently, Hanyu Pharmaceutical announced that its independently developed GLP-1 Liraglutide Injection has been approved by the FDA for marketing as the first generic version and has officially landed in the United States. As we all know, GLP-1 drugs have become the focus of the market in recent years due to their significant efficacy in reducing blood sugar and weight loss. However, precisely because of the skyrocketing demand, this type of drug has repeatedly faced problems of insufficient production and supply. The launch of Hanyu Pharmaceutical’s liraglutide generics in the U.S. market is not only an important breakthrough for Hanyu Pharmaceuticals in the international market, but also marks the imminent expansion of China’s liraglutide generics. Estimated peak sales of $135 million Liraglutide is a human glucagon-like peptide-1 (GLP-1) analog that can activate human GLP-1 receptors, promote insulin secretion, inhibit glucagon secretion, delay gastric emptying, and increase satiety, thereby reducing blood sugar ...
- Source: drugdu
- 463
- January 6, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.